(COTY) Coty - NYSE
Sector: Consumer Defensive | Industry: Household & Personal Products | Exchange: NYSE (USA) | Market Cap: 1.787m USD | Total Return: -59% in 12m
Avg Turnover: 16.3M
EPS Trend: -96.3%
Qual. Beats: -2
Rev. Trend: -1.4%
Qual. Beats: 0
Warnings
High Debt/EBITDA (35.3) with thin interest coverage (-1.6)
Interest Coverage Ratio -1.6 is critical
Altman Z'' -1.85 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Coty Inc. is a global beauty firm operating through Prestige and Consumer Beauty segments. The company maintains a diverse portfolio of fragrance, color cosmetics, and skincare products, leveraging high-profile licensed brands such as Burberry, Gucci, and Calvin Klein alongside mass-market labels like CoverGirl and Rimmel. Distribution spans department stores, e-commerce, and traditional retail channels.
The beauty industry operates on a high-margin licensing model where manufacturers pay royalties to luxury fashion houses for the right to produce branded scents and cosmetics. In the Personal Care Products sub-industry, brand equity and global distribution networks serve as the primary barriers to entry against smaller independent competitors. You can find more detailed financial metrics on ValueRay to assist in your analysis.
Founded in 1904, Coty is headquartered in New York and functions as a subsidiary of JAB Beauty B.V. The company’s geographic reach includes duty-free shops and direct-to-consumer platforms, balancing luxury prestige positioning with broad-scale consumer retail presence.
- Prestige fragrance demand drives margin expansion through high-end brand licensing
- Consumer beauty segment faces competitive pressure from mass-market private labels
- Strategic expansion into skincare categories diversifies revenue beyond traditional cosmetics
- High debt levels and interest costs impact net income and valuation
- Growth in travel retail and e-commerce channels accelerates global market penetration
| Net Income: -532.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.10 > 1.0 |
| NWC/Revenue: -7.27% < 20% (prev -7.15%; Δ -0.11% < -1%) |
| CFO/TA 0.05 > 3% & CFO 505.0m > Net Income -532.6m |
| Net Debt (3.55b) to EBITDA (100.7m): 35.26 < 3 |
| Current Ratio: 0.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (879.9m) vs 12m ago 0.89% < -2% |
| Gross Margin: 60.66% > 18% (prev 65.23%; Δ -4.58% > 0.5%) |
| Asset Turnover: 53.36% > 50% (prev 52.34%; Δ 1.02% > 0%) |
| Interest Coverage Ratio: -1.62 > 6 (EBIT TTM -358.1m / Interest Expense TTM 220.9m) |
| A: -0.04 (Total Current Assets 1.94b - Total Current Liabilities 2.36b) / Total Assets 10.2b |
| B: -0.56 (Retained Earnings -5.74b / Total Assets 10.2b) |
| C: -0.03 (EBIT TTM -358.1m / Avg Total Assets 10.8b) |
| D: 0.45 (Book Value of Equity 3.09b / Total Liabilities 6.87b) |
| Altman-Z'' = -1.85 = D |
| DSRI: 1.02 (Receivables 565.2m/572.9m, Revenue 5.79b/6.00b) |
| GMI: 1.08 (GM 65.23% / 60.66%) |
| AQI: 0.97 (AQ_t 0.73 / AQ_t-1 0.75) |
| SGI: 0.96 (Revenue 5.79b / 6.00b) |
| TATA: -0.10 (NI -532.6m - CFO 505.0m) / TA 10.2b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of June 15, 2026, the stock is trading at USD 2.07 with a total of 7,011,150 shares traded.
Over the past week, the price has changed by +5.61%,
over one month by -2.82%,
over three months by -6.33% and
over the past year by -59.01%.
Coty has received a consensus analysts rating of 3.65. Therefore, it is recommended to hold COTY.
- StrongBuy: 7
- Buy: 1
- Hold: 10
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 3.2 | 53.1% |
P/E Forward = 6.2189
P/S = 0.3087
P/B = 0.5668
P/EG = 0.1783
Revenue TTM = 5.79b USD
EBIT TTM = -358.1m USD
EBITDA TTM = 100.7m USD
Long Term Debt = 3.17b USD (from longTermDebt, last quarter)
Short Term Debt = 65.8m USD (from shortTermDebt, last quarter)
Debt = 3.82b USD (from shortLongTermDebtTotal, last quarter) + Leases 253.5m
Net Debt = 3.55b USD (calculated: Debt 3.82b - CCE 270.2m)
Enterprise Value = 5.34b USD (1.79b + Debt 3.82b - CCE 270.2m)
Interest Coverage Ratio = -1.62 (Ebit TTM -358.1m / Interest Expense TTM 220.9m)
EV/FCF = 17.19x (Enterprise Value 5.34b / FCF TTM 310.5m)
FCF Yield = 5.82% (FCF TTM 310.5m / Enterprise Value 5.34b)
FCF Margin = 5.36% (FCF TTM 310.5m / Revenue TTM 5.79b)
Net Margin = -9.20% (Net Income TTM -532.6m / Revenue TTM 5.79b)
Gross Margin = 60.66% ((Revenue TTM 5.79b - Cost of Revenue TTM 2.28b) / Revenue TTM)
Gross Margin QoQ = 56.03% (prev 59.42%)
Tobins Q-Ratio = 0.52 (Enterprise Value 5.34b / Total Assets 10.2b)
Interest Expense / Debt = 5.78% (Interest Expense 220.9m / Debt 3.82b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -282.9m (EBIT -358.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.82 (Total Current Assets 1.94b / Total Current Liabilities 2.36b)
Debt / Equity = 1.24 (Debt 3.82b / totalStockholderEquity, last quarter 3.09b)
Debt / EBITDA = 35.26 (Net Debt 3.55b / EBITDA 100.7m)
Debt / FCF = 11.44 (Net Debt 3.55b / FCF TTM 310.5m)
Total Stockholder Equity = 3.52b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.91% (Net Income -532.6m / Total Assets 10.2b)
RoE = -15.12% (Net Income TTM -532.6m / Total Stockholder Equity 3.52b)
RoCE = -5.35% (EBIT -358.1m / Capital Employed (Equity 3.52b + L.T.Debt 3.17b))
RoIC = -3.69% (negative operating profit) (NOPAT -282.9m / Invested Capital 7.67b)
WACC = 6.28% (E(1.79b)/V(5.61b) * Re(9.93%) + D(3.82b)/V(5.61b) * Rd(5.78%) * (1-Tc(0.21)))
Discount Rate = 9.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: -2.09%
[DCF] Terminal Value 73.35% ; FCFF base≈330.1m ; Y1≈293.4m ; Y5≈243.6m
[DCF] Fair Price = 0.39 (EV 3.90b - Net Debt 3.55b = Equity 345.5m / Shares 880.5m; r=8.35% [WACC [floored]]; 5y FCF grow -13.61% → 2.50% )
EPS Correlation: -96.34 | EPS CAGR: -40.09% | SUE: -0.95 | # QB: -2
Revenue Correlation: -1.38 | Revenue CAGR: -0.05% | SUE: 0.45 | # QB: 0
EPS next Quarter (2026-09-30): EPS=0.15 | Chg30d=+1.60% | Revisions=-27% | Analysts=9
EPS current Year (2026-06-30): EPS=0.24 | Chg30d=+0.58% | Revisions=-26% | GrowthEPS=+10.5% | GrowthRev=-2.6%
EPS next Year (2027-06-30): EPS=0.37 | Chg30d=-0.95% | Revisions=-12% | GrowthEPS=+50.8% | GrowthRev=+0.9%
[Analyst] Revisions Ratio: -27%